0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA |

Highlights FREE

JAMA. 2013;310(23):2479-2481. doi:10.1001/jama.2013.5468.
Text Size: A A A
Published online

Dual antiplatelet therapy is currently recommended for at least 12 months after implantation of a drug-eluting stent. In a multicenter randomized trial involving 3119 patients undergoing percutaneous coronary intervention with zotarolimus-eluting stents for stable coronary artery disease or low-risk acute coronary syndrome, Ferres and colleagues found that 3 months of dual antiplatelet therapy (100-200 mg of aspirin daily and 75 mg of clopidogrel daily) was noninferior to 12 months of therapy on a composite outcome of death, myocardial infarction, stroke, or major bleeding, with no increased risk of stent thrombosis.

Chronic periodontitis—an inflammatory disorder of the supporting structure of the teeth—is common in persons with diabetes. To assess whether nonsurgical periodontal treatment (scaling, root planing, and chlorhexidine rinse) improves hemoglobin A1c levels in patients with type 2 diabetes, Engebretson and colleagues randomly assigned 514 patients with untreated moderate or advanced periodontitis to receive periodontal treatment or no treatment for 6 months. The authors found that periodontal therapy did not improve glycemic control.

Patients with acute heart failure and renal dysfunction are at risk of inadequate decongestion and worsening renal function. In a multicenter randomized trial that enrolled 360 hospitalized patients with acute heart failure and renal dysfunction, Chen and colleagues tested 2 independent hypotheses that, compared with placebo, the addition of low-dose dopamine or low-dose nesiritide to diuretic therapy would enhance decongestion and preserve renal function. The authors report that neither treatment strategy enhanced decongestion or improved renal function compared with placebo.

Calcium-channel blockers are metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. In a population-based retrospective cohort study involving more than 190 000 older adults who were newly prescribed clarithromycin or azithromycin while taking a calcium-channel blocker, Gandhi and colleagues found that concurrent use of clarithromycin (an inhibitor of CYP3A4) but not azithromycin was associated with a small but statistically significant greater short-term risk of hospitalization with acute kidney injury.

In an analysis of publicly available data from the grant registries of 13 pharmaceutical companies and 1 medical device company, Rothman and colleagues examined relationships between medical communication companies (MCCs)—key providers of information to physicians and consumers—and the drug and device industry. Among the authors’ findings were that MCCs receive substantial support from drug and device companies; the majority of MCCs are for-profit, conduct continuing medical education (CME) programs, track physicians’ website behavior, and may share personal physician data with unnamed third parties. In an Editorial, Schwartz and Woloshin discuss implications of industry funding of MCCs.

Related Editorial

CLINICAL REVIEW & EDUCATION

A 20-year-old man presented with a mildly pruritic, progressive rash that began on his scalp and spread to his neck, back, chest, and thighs. A trial of oral cephalexin was not helpful. He denied other medication use, travel, or illicit drug use. Examination revealed numerous grouped vesicles and bullae coalescing into annular plaques, on an erythematous base with central clearing and scale. The patient was afebrile and appeared well. What would you do next?

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.